Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SAB Biotherapeutics (SABS)
NASDAQ:SABS
SAB Biotherapeutics (SABS) Stock Price & Analysis
60 Followers
SABS Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.38 - $10.50
Previous Close$3.45
Volume227.12K
Average Volume (3M)12.30K
Market Cap
$27.95M
Enterprise Value$34.05M
Total Cash (Recent Filing)$2.43M
Total Debt (Recent Filing)$4.65M
Price to Earnings (P/E)-0.5
Beta1.40
Next Earnings
Aug 07, 2024EPS Estimate
-$1.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.74
Shares Outstanding9,225,494
10 Day Avg. Volume11,424
30 Day Avg. Volume12,296
Standard Deviation0.31
R-Squared0.03
Alpha-0.06
Financial Highlights & Ratios
Price to Book (P/B)2.20
Price to Sales (P/S)1.33
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.61
Enterprise Value/Gross Profit1.42
Enterprise Value/Ebitda-1.47
Forecast
1Y Price Target
$15.50Price Target Upside411.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
SAB Biotherapeutics News
PremiumCompany Announcements
SAB Biotherapeutics Enhances Board with Medical Expert
PremiumPress Releases
SAB Biotherapeutics Provides SAB-142 Trial Update
PremiumCompany Announcements
SAB Biotherapeutics Advances SAB-142 in Phase One TrialsBulls Say, Bears Say
Bulls Say
Clinical Development ProgressThe phase 1 trial for SAB-142 is advancing as planned, with the first patient already dosed and expectations to move into later stage trials, signaling a strong progression in the company's pipeline.
Funding And Financial PositionSAB has secured funding through a private placement that provided significant gross proceeds, ensuring sufficient current and future cash to fund operations and research programs.
Market Interest And PotentialRecent FDA approval of a new immunotherapy for type 1 diabetes and a high-value acquisition in the sector underscore a robust market interest, augmenting the potential for SAB's similar therapies.
Bears Say
Earnings MissSAB reported 4Q23 EPS of ($3.38), missing analyst estimates by a significant margin.
Earnings RevisionAnalysts have adjusted their 4Q23 EPS estimate for SAB from ($0.06) to ($0.64), indicating a negative earnings revision.
Financial PerformanceThe unexpected one-time charges have led to a concerning decrease in the full-year 2024 EPS estimate for SAB.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SABS FAQ
What was SAB Biotherapeutics’s price range in the past 12 months?
SAB Biotherapeutics lowest stock price was $3.38 and its highest was $10.50 in the past 12 months.
What is SAB Biotherapeutics’s market cap?
Currently, no data Available
When is SAB Biotherapeutics’s upcoming earnings report date?
SAB Biotherapeutics’s upcoming earnings report date is Aug 07, 2024 which is in 78 days.
How were SAB Biotherapeutics’s earnings last quarter?
SAB Biotherapeutics released its earnings results on May 20, 2024. The company reported -$0.54 earnings per share for the quarter, beating the consensus estimate of -$0.96 by $0.42.
Is SAB Biotherapeutics overvalued?
According to Wall Street analysts SAB Biotherapeutics’s price is currently Undervalued.
Does SAB Biotherapeutics pay dividends?
SAB Biotherapeutics does not currently pay dividends.
What is SAB Biotherapeutics’s EPS estimate?
SAB Biotherapeutics’s EPS estimate is -$1.1.
How many shares outstanding does SAB Biotherapeutics have?
SAB Biotherapeutics has 9,225,494 shares outstanding.
What happened to SAB Biotherapeutics’s price movement after its last earnings report?
SAB Biotherapeutics reported an EPS of -$0.54 in its last earnings report, beating expectations of -$0.96. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of SAB Biotherapeutics?
Among the largest hedge funds holding SAB Biotherapeutics’s share is RA Capital Management. It holds SAB Biotherapeutics’s shares valued at N/A.
---
SAB Biotherapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$15.50 (411.55% Upside)
$15.50 (411.55% Upside)
Hedge Fund Trend
Decreased
By 237.2K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.58%
12-Months-Change
Fundamentals
Return on Equity
-95.51%
Trailing 12-Months
Asset Growth
64.90%
Trailing 12-Months
Company Description
SAB Biotherapeutics
Blue Calypso Inc is engaged in the development, sales, delivery and licensing of technology and intellectual property focused on mobile shopper engagement, digital word of mouth and location-based marketing and advertising. Its solutions include mobile engagement, POP and merchandise tracking, mobile plant tag engagement. The company derives its revenues from the cloud-based consumption of its technology platform, consulting fees and licensing of its technologies.
---
SABS Stock 12 Month Forecast
Average Price Target
$15.50
▲(411.55% Upside)
Technical Analysis
Best Analysts Covering SABS
1 Year
1 Year Success Rate
0/12 ratings generated profit
1 Year Average Return
-52.45%
reiterated a buy rating 2 months ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -52.45% per trade.
---